HQH
abrdn Healthcare InvestorsHQH
HQH
About: abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
71% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 24
0.9% less ownership
Funds ownership: 25.0% [Q4 2024] → 24.1% (-0.9%) [Q1 2025]
3% less capital invested
Capital invested by funds: $194M [Q4 2024] → $189M (-$4.88M) [Q1 2025]
12% less funds holding
Funds holding: 116 [Q4 2024] → 102 (-14) [Q1 2025]
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
Research analyst outlook
We haven’t received any recent analyst ratings for HQH.
Financial journalist opinion
Positive
Seeking Alpha
3 weeks ago
HQH: Efficient Fund To Collect Income From Healthcare
I maintain my buy rating on HQH for its high 13.6% yield, strong dividend coverage, and efficient healthcare sector diversification. HQH trades at an 8% discount to NAV, offering an attractive entry point compared to peers, despite recent price declines. The fund is well-positioned to benefit from long-term healthcare sector growth, driven by rising spending and health-conscious trends.
Neutral
Seeking Alpha
3 weeks ago
HQH: A Good Balance Of Returns And Risks In The Healthcare Sector
HQH offers a compelling mix of high yield and growth exposure to healthcare, trading at a discount to NAV with recent outperformance versus benchmarks. The fund benefits from strong healthcare industry tailwinds—aging populations and innovation—while active management and share buybacks support narrowing the NAV discount. A robust 13.6% market yield and a fair value estimate 36% above current price highlight significant upside, though distribution sustainability must be monitored.
Positive
Seeking Alpha
1 month ago
2 Fat Dividends For A Lifetime Of Passive Income
Berkshire Hathaway's portfolio of cash flow generators allows financial independence and opportunistic moves without financing dependencies. The "Income Method" aims to replicate Mr. Buffett's financial independence by prioritizing the generation of income streams from our personal portfolios. We discuss our top picks with yields of up to 15%.
Positive
Seeking Alpha
2 months ago
8 Closed-End Fund Buys (And 2 Sells) In The Month Of March 2025
This month we got some increased market volatility, allowing me to put some of my cash pile to work in my closed-end fund portfolio. I also sold out of two positions, as they were starting to become on the more expensive side in terms of discounts/premiums. Adding to my positions regularly every month increases my cash flow annually, and even every month it grows.
Positive
Seeking Alpha
3 months ago
Bargain Alert: 2 Big Dividends, Up To 10% Yield
Immunize your retirement from market noise with recurring dividends. We discuss two essential sectors for reliable income generation, regardless of economic conditions. Discover our top picks with up to 10% yields.
Positive
Seeking Alpha
3 months ago
I Am Loading Up Big Dividends For My Golden Years
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.
Positive
Seeking Alpha
4 months ago
HQH: Improved Fundamentals, Strong Dividend Support
HQH offers a high dividend yield of 13.6%, making it attractive for income-focused investors, despite potential tax consequences. The fund trades at a 7.86% discount to NAV, presenting a good entry point, especially with anticipated interest rate cuts and increased healthcare spending. HQH's portfolio is heavily concentrated in Biotechnology (64.6%), posing sector-specific risks but also benefiting from projected growth in biotech and healthcare spending.
Neutral
Seeking Alpha
4 months ago
Aberdeen Or 'abrdn' - Either Way The Coverage Looks A Bit Thin
Closed-end funds offer unique advantages, like buying at discounts and leveraging with institutionally priced debt, making them ideal income-generating vehicles. Cash distributions are key contributors to total return, but it is essential to be sure they are actually covered by fund earnings. Some investors overly prioritize distribution yields, neglecting the importance of considering total return as a whole.
Positive
Seeking Alpha
5 months ago
Don't Miss The Dividend Train, Yields Up To 15%
For over 400 years, dividends have been a steady form of capital from the markets to your account. Dividends can generate dependable and powerful paychecks. We discuss two big yields from dependable sectors.
Negative
Seeking Alpha
5 months ago
HQH: Not For Income Investors
I maintain a sell rating on the abrdn Healthcare Investors fund due to its incongruence with income investing and managed distribution plans. HQH has underperformed the Nasdaq Biotechnology Index and iShares Biotechnology ETF, highlighting its inability to generate alpha versus more tax-efficient alternatives. The fund's high yield is unsustainable, relying on capital gains and potentially forcing premature sales, which is unsuitable for income-oriented investors.
Charts implemented using Lightweight Charts™